{
 "id": "ep3n598mkq",
 "slug": "neoadjuvant-hormonal-therapy",
 "title": "Neoadjuvant hormonal therapy",
 "updated": "2026-09-30",
 "topic_path": [
  {
   "id": "life",
   "label": "Life and health",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life"
  },
  {
   "id": "life.health",
   "label": "Human health and medicine",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life.health"
  },
  {
   "id": "life.health.medicines",
   "label": "Medicines and therapeutics",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.medicines"
  },
  {
   "id": "life.health.medicines.cancer-chemotherapy",
   "label": "Cancer chemotherapy and regimens",
   "api_url": "https://www.edgepedia.org/api/v1/topics/life.health.medicines.cancer-chemotherapy"
  }
 ],
 "geo": [
  {
   "id": "geo.nongeo.t1946.life.health.medicines.cancer-chemotherapy",
   "label": "Non-geographic · 1946 to 2000: Cancer chemotherapy and regimens",
   "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.medicines.cancer-chemotherapy",
   "path": [
    {
     "id": "geo.nongeo",
     "label": "Non-geographic",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo"
    },
    {
     "id": "geo.nongeo.t1946",
     "label": "Non-geographic · 1946 to 2000",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946"
    },
    {
     "id": "geo.nongeo.t1946.life",
     "label": "Life and health",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life"
    },
    {
     "id": "geo.nongeo.t1946.life.health",
     "label": "Human health and medicine",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health"
    },
    {
     "id": "geo.nongeo.t1946.life.health.medicines",
     "label": "Medicines and therapeutics",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.medicines"
    },
    {
     "id": "geo.nongeo.t1946.life.health.medicines.cancer-chemotherapy",
     "label": "Cancer chemotherapy and regimens",
     "api_url": "https://www.edgepedia.org/api/v1/geo/geo.nongeo.t1946.life.health.medicines.cancer-chemotherapy"
    }
   ]
  }
 ],
 "excerpt": "Neoadjuvant hormonal therapy is the administration of hormone-blocking drugs before definitive local treatment, chiefly surgery or radiotherapy, to shrink hormone-sensitive tumors, most often prostate cancer and breast cancer.",
 "snippet": "Neoadjuvant hormonal therapy is the administration of hormone-blocking drugs before definitive local treatment, chiefly surgery or radiotherapy, to shrink hormone-sensitive tumors, most often prostate cancer and breast cancer.",
 "node": "life.health.medicines.cancer-chemotherapy",
 "markdown": "# Neoadjuvant hormonal therapy\n\nNeoadjuvant hormonal therapy is the administration of hormone-blocking drugs before definitive local treatment, chiefly surgery or radiotherapy, to shrink hormone-sensitive tumors, most often prostate cancer and breast cancer. \n\n| Key fact | Detail |\n|---|---|\n| Main uses | Prostate cancer (with radiotherapy for high-risk/locally advanced disease) and postmenopausal HR-positive/HER2-negative breast cancer[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC12784934/)[4](https://www.mdpi.com/2072-6694/13/4/902) |\n| Typical prostate regimen | In trials, an LHRH agonist or antagonist, with or without an antiandrogen, was given for 3 to 6 months before surgery; neoadjuvant ADT before prostatectomy is not routine care outside clinical trials[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC12784934/) |\n| Typical breast regimen | An aromatase inhibitor for 4 to 8 months in postmenopausal women[4](https://www.mdpi.com/2072-6694/13/4/902)[2](https://ascopubs.org/doi/10.1200/JCO.20.03399) |\n| Effect before prostatectomy | Up to 50% reduction in positive margins and improved downstaging, but no overall, metastasis-free, or biochemical recurrence-free survival benefit[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC12784934/)[5](https://pubmed.ncbi.nlm.nih.gov/33586699/) |\n| Effect before radiotherapy | Improved cancer-specific survival (HR 0.51), disease-free survival (HR 0.51), and biochemical progression-free survival (HR 0.54) in high-risk disease[5](https://pubmed.ncbi.nlm.nih.gov/33586699/) |\n| Duration question | 8 months of androgen deprivation gave lower positive margins than 3 months (12% vs 23%) but more hot flushes (87% vs 72%)[6](https://doi.org/10.1016/s0022-5347(05)65971-x) |\n| Guideline status | Not recommended before prostatectomy outside clinical trials; standard of care with radiotherapy in high-risk prostate cancer[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC12784934/)[5](https://pubmed.ncbi.nlm.nih.gov/33586699/) |\n\n## How it works\n\nIn prostate cancer, the drugs suppress androgen signaling, which hormone-sensitive tumor cells require for survival. LHRH agonists (leuprolide, triptorelin, goserelin, [histrelin](https://www.edgepedia.org/histrelin)) stimulate the LHRH receptor continuously, causing a transient rise in luteinizing hormone, testosterone, and PSA (the \"flare\" phenomenon) before receptor downregulation lowers testosterone; the antagonist degarelix blocks the receptor directly and lowers testosterone without a flare.[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC7759181/) Nonsteroidal antiandrogens such as bicalutamide, flutamide, and nilutamide inhibit binding of DHT and testosterone to the androgen receptor, while abiraterone inhibits CYP17A1-mediated androgen synthesis in the adrenal glands, testes, and tumor tissue.[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC7759181/)\n\nAndrogen suppression also primes the tumor for radiotherapy: suppression of androgen receptor signaling heightens sensitivity to radiation by blocking non-homologous end-joining [DNA repair](https://www.edgepedia.org/dna-repair).[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC7759181/) In breast cancer, the prerequisite is hormone sensitivity: aromatase inhibitors work only when the tumor's growth is estrogen-driven, which is why use is concentrated in hormone receptor-positive disease, a group that accounts for approximately 70% of all breast cancers.[4](https://www.mdpi.com/2072-6694/13/4/902)\n\n## How it is done\n\nBefore radical prostatectomy, trials most often gave an LHRH agonist or antagonist with or without a first-generation antiandrogen such as bicalutamide for three to six months.[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC12784934/) In the largest duration trial, 547 men received monthly leuprolide 7.5 mg plus flutamide 250 mg three times daily, randomized to 3 or 8 months.[6](https://doi.org/10.1016/s0022-5347(05)65971-x) Response is monitored with serum PSA and prostate volume: in that trial mean PSA fell 98% to 0.12 µg/l after 3 months and a further 57% to 0.052 µg/l by 8 months, while transrectal ultrasound showed volume fell 37% from a mean of 40.6 to 25.4 cc.[6](https://doi.org/10.1016/s0022-5347(05)65971-x) At resection, pathological complete response is defined as absence of morphologically recognizable carcinoma in the specimen, and minimal residual disease as residual tumor of maximum diameter 5 mm or less.[7](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1217303/full) In breast cancer, [neoadjuvant endocrine therapy](https://www.edgepedia.org/neoadjuvant-endocrine-therapy) with an aromatase inhibitor is given to postmenopausal women with HR-positive/HER2-negative tumors, most studies reporting downstaging using 3 to 6 months, and guidelines considering 4 to 8 months a validated duration.[2](https://ascopubs.org/doi/10.1200/JCO.20.03399)[4](https://www.mdpi.com/2072-6694/13/4/902)\n\n## Origin\n\nThe approach drew little attention until the 1980s, when reversible and less toxic forms of hormonal therapy became available.[8](https://www.sciencedirect.com/science/article/abs/pii/S1078143906000925) The first prospective randomized trial of neoadjuvant androgen deprivation plus radical prostatectomy versus surgery alone, using 3 months of flutamide and leuprolide in 142 men, was reported by Fernand Labrie and colleagues in *Urology* in 1994, and showed a significant reduction in positive surgical margins and increased pathological downstaging.[9](https://doi.org/10.1016/s0090-4295(94)80241-6)[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC7759181/) The duration question was addressed by Martin E. Gleave and colleagues of the Canadian Uro-Oncology Group, whose randomized comparison of 3 versus 8 months of therapy in 547 men appeared in *The Journal of Urology* in 2001; 8 months lowered positive margin rates (12% vs 23%, p = 0.0106) at the cost of more hot flushes (87% vs 72%).[6](https://doi.org/10.1016/s0022-5347(05)65971-x) Since the 1990s, randomized trials have consistently improved pathological parameters, including tumor downstaging, reduced extraprostatic extension, seminal vesicle invasion, and positive margins, without improving cancer-specific or overall survival.[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC7759181/)\n\n## Variants\n\nIntensification combines androgen deprivation with docetaxel or androgen receptor signaling inhibitors (abiraterone, enzalutamide, apalutamide), often with LHRH analogs.[10](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1796138/full) In a pooled analysis of two phase II trials in very-high-risk disease, pathological complete response or minimal residual disease was 28% with ADT plus docetaxel and 31% with ADT plus abiraterone, versus 2% with ADT alone, and 3-year biochemical progression-free survival was 41.9% with ADT alone, 51.1% with ADT plus docetaxel, and 61.2% with ADT plus abiraterone (p = 0.037).[7](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1217303/full) The ARNEO phase 2 trial randomized high-risk patients to 3 months of degarelix plus apalutamide or degarelix plus placebo before surgery; at a median follow-up of 54 months biochemical recurrence-free survival did not differ between arms, with minimal residual disease failing to predict outcome.[11](https://www.sciencedirect.com/science/article/abs/pii/S2588931125003311) A phase 3 double-blind trial randomized 2109 men with high-risk localized or locally advanced disease to ADT plus apalutamide (240 mg/day) or placebo for six 28-day cycles before and after radical prostatectomy: pathological complete response or minimal residual disease was 8.9% versus 1.0% (OR 10.17, P<0.001), and at a median follow-up of 61.7 months 5-year metastasis-free survival was 78.2% versus 73.5% (HR 0.80, P = 0.02).[12](https://europepmc.org/article/MED/42223077)\n\n## Applications\n\nA meta-analysis of 16 studies in high-risk prostate cancer found that neoadjuvant hormone therapy before radical prostatectomy significantly decreased lymph node involvement (RR 0.69, 95% CI 0.56–0.87) and increased pathological downstaging (RR 2.62, 95% CI 1.22–5.61) and organ confinement (RR 2.24, 95% CI 1.54–3.25), but did not improve overall survival or biochemical progression-free survival.[5](https://pubmed.ncbi.nlm.nih.gov/33586699/) Before radiotherapy, the same therapy was associated with significant benefits in cancer-specific survival (HR 0.51), disease-free survival (HR 0.51), and biochemical progression-free survival (HR 0.54), and the meta-analysis concluded that short-term hormone therapy combined with radiotherapy is recommended for standard practice, but not for patients undergoing prostatectomy.[5](https://pubmed.ncbi.nlm.nih.gov/33586699/) Current international guidelines do not routinely recommend neoadjuvant systemic therapy before radical prostatectomy outside clinical trials, while endorsing ADT with radiotherapy as standard of care for high-risk and locally advanced disease.[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC12784934/) In breast cancer, neoadjuvant endocrine therapy for 4 to 8 months is a validated treatment in postmenopausal women with HR-positive/HER2-negative disease to improve surgical outcome and allow breast-conserving surgery, and the ASCO guideline states an aromatase inhibitor may be offered to increase locoregional treatment options.[4](https://www.mdpi.com/2072-6694/13/4/902)[2](https://ascopubs.org/doi/10.1200/JCO.20.03399)\n\n## Limitations and alternatives\n\nToxicity during the neoadjuvant window is substantial. In a network meta-analysis, classical neoadjuvant hormonal therapy had the best tolerability, with hot flashes as its main adverse reaction (30% at any grade, 5% grade 2), while novel hormonal therapy showed higher rates of hypokalemia (8% any grade, 3% grades 3–4), diarrhea (15% any grade, 2% grades 3–4), and fatigue (25% any grade, 3% grades 2–4).[10](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1796138/full) In the 3 versus 8-month trial, the 8-month arm had more newly reported adverse events (4.5 vs 2.9) and more hot flushes (87% vs 72%).[6](https://doi.org/10.1016/s0022-5347(05)65971-x) Compared with neoadjuvant chemotherapy, endocrine therapy trades response depth for tolerability. In postmenopausal women, aromatase inhibitors outperformed tamoxifen in early phase III trials, and a meta-analysis of 20 randomized trials (3,490 patients) found response and breast-conserving surgery rates comparable to neoadjuvant chemotherapy but significantly greater toxicity in the chemotherapy arms; significant pathological response with endocrine therapy remains rare.[4](https://www.mdpi.com/2072-6694/13/4/902)[2](https://ascopubs.org/doi/10.1200/JCO.20.03399) The evidence on chemohormonal intensification before surgery is unsettled. One account of CALGB 90203, a trial of radical prostatectomy with or without neoadjuvant [chemohormonal therapy](https://www.edgepedia.org/chemohormonal-therapy) in localized high-risk disease reported by James A. Eastham and colleagues in *Journal of Clinical Oncology* in 2020, describes improved 10-year overall survival (80% vs 74%, HR 0.61, 95% CI 0.4–0.94),[13](https://doi.org/10.1200/jco.20.00315)[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC7759181/) while another account states the trial did not meet its primary endpoint of 3-year biochemical progression-free survival and that NCCN guidelines do not recommend neoadjuvant ADT or chemotherapy before prostatectomy outside clinical trials.[14](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1693222/full) The published trial literature does not quantify bone loss during the neoadjuvant window and does not address whether delaying surgery worsens outcomes; TROG 96.01 randomized men to radiotherapy alone, radiotherapy with 3 months of neoadjuvant androgen deprivation, or radiotherapy with 6 months of neoadjuvant androgen deprivation, providing a direct randomized comparison of 3 versus 6 months of androgen deprivation.[11](https://www.sciencedirect.com/science/article/abs/pii/S2588931125003311)\n\n## References\n\n---\n*Topic: Encyclopedia › Life and health › Human health and medicine › Medicines and therapeutics › Cancer chemotherapy and regimens*\n\n*Initially written Sep 29, 2026 · Reviewed: Sep 30, 2026 · Edited: Sep 30, 2026 · Last review: Sep 30, 2026*\n\n*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*\n\nLicense: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license\n",
 "same_as": [],
 "url": "https://www.edgepedia.org/neoadjuvant-hormonal-therapy",
 "markdown_url": "https://www.edgepedia.org/neoadjuvant-hormonal-therapy.md",
 "license": {
  "name": "Edgepedia Community License 1.0",
  "url": "https://www.edgepedia.org/edgepedia/license",
  "summary": "Free with credit, commercial use included. AI training is open to everyone. For other uses, organizations over USD 100M in revenue or 100M monthly users license separately.",
  "spdx": "LicenseRef-Edgepedia-Community-1.0"
 },
 "credit": "\"Neoadjuvant hormonal therapy\", Edgepedia (EdgeChat), https://www.edgepedia.org/neoadjuvant-hormonal-therapy. Edgepedia Community License 1.0.",
 "credit_md": "\"[Neoadjuvant hormonal therapy](https://www.edgepedia.org/neoadjuvant-hormonal-therapy)\", Edgepedia (EdgeChat), [https://www.edgepedia.org/neoadjuvant-hormonal-therapy](https://www.edgepedia.org/neoadjuvant-hormonal-therapy). [Edgepedia Community License 1.0](https://www.edgepedia.org/edgepedia/license).",
 "credit_html": "\"<a href=\"https://www.edgepedia.org/neoadjuvant-hormonal-therapy\">Neoadjuvant hormonal therapy</a>\", Edgepedia (EdgeChat), <a href=\"https://www.edgepedia.org/neoadjuvant-hormonal-therapy\">https://www.edgepedia.org/neoadjuvant-hormonal-therapy</a>. <a href=\"https://www.edgepedia.org/edgepedia/license\">Edgepedia Community License 1.0</a>.",
 "speakable": "Neoadjuvant hormonal therapy is the administration of hormone-blocking drugs before definitive local treatment, chiefly surgery or radiotherapy, to shrink hormone-sensitive tumors, most often prostate cancer and breast cancer."
}